Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis.

Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Alemán JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR.

Cell Metab. 2008 Feb;7(2):125-34. doi: 10.1016/j.cmet.2007.11.013.

2.

Sterol carrier protein-2 deficiency attenuates diet-induced dyslipidemia and atherosclerosis in mice.

He H, Wang J, Yannie PJ, Kakiyama G, Korzun WJ, Ghosh S.

J Biol Chem. 2018 Jun 15;293(24):9223-9231. doi: 10.1074/jbc.RA118.002290. Epub 2018 Apr 26.

PMID:
29700117
3.

Lipid and lipoprotein dysregulation in insulin resistant states.

Avramoglu RK, Basciano H, Adeli K.

Clin Chim Acta. 2006 Jun;368(1-2):1-19. Epub 2006 Feb 9. Review.

PMID:
16480697
4.

Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice.

Han S, Liang CP, Westerterp M, Senokuchi T, Welch CL, Wang Q, Matsumoto M, Accili D, Tall AR.

J Clin Invest. 2009 Apr;119(4):1029-41. doi: 10.1172/JCI36523. Epub 2009 Mar 9.

5.

Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance.

Mulvihill EE, Assini JM, Lee JK, Allister EM, Sutherland BG, Koppes JB, Sawyez CG, Edwards JY, Telford DE, Charbonneau A, St-Pierre P, Marette A, Huff MW.

Diabetes. 2011 May;60(5):1446-57. doi: 10.2337/db10-0589. Epub 2011 Apr 6.

6.

[Diabetic dyslipidaemia and the atherosclerosis].

Márk L, Dani G.

Orv Hetil. 2016 May 8;157(19):746-52. doi: 10.1556/650.2016.30441. Review. Hungarian.

PMID:
27133274
7.

Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance.

Mulvihill EE, Allister EM, Sutherland BG, Telford DE, Sawyez CG, Edwards JY, Markle JM, Hegele RA, Huff MW.

Diabetes. 2009 Oct;58(10):2198-210. doi: 10.2337/db09-0634. Epub 2009 Jul 10.

8.

A diet-induced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome.

Hartvigsen K, Binder CJ, Hansen LF, Rafia A, Juliano J, Hörkkö S, Steinberg D, Palinski W, Witztum JL, Li AC.

Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):878-85. Epub 2007 Jan 25.

PMID:
17255537
9.

Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.

Mulvihill EE, Assini JM, Sutherland BG, DiMattia AS, Khami M, Koppes JB, Sawyez CG, Whitman SC, Huff MW.

Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):742-8. doi: 10.1161/ATVBAHA.109.201095. Epub 2010 Jan 28.

PMID:
20110573
10.

New and emerging regulators of intestinal lipoprotein secretion.

Xiao C, Dash S, Morgantini C, Lewis GF.

Atherosclerosis. 2014 Apr;233(2):608-15. doi: 10.1016/j.atherosclerosis.2013.12.047. Epub 2014 Jan 21. Review.

PMID:
24534456
11.

Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.

Bril F, Sninsky JJ, Baca AM, Superko HR, Portillo Sanchez P, Biernacki D, Maximos M, Lomonaco R, Orsak B, Suman A, Weber MH, McPhaul MJ, Cusi K.

J Clin Endocrinol Metab. 2016 Feb;101(2):644-52. doi: 10.1210/jc.2015-3111. Epub 2015 Dec 16.

PMID:
26672634
12.

Myeloid cell-specific ATP-binding cassette transporter A1 deletion has minimal impact on atherogenesis in atherogenic diet-fed low-density lipoprotein receptor knockout mice.

Bi X, Zhu X, Gao C, Shewale S, Cao Q, Liu M, Boudyguina E, Gebre AK, Wilson MD, Brown AL, Parks JS.

Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1888-99. doi: 10.1161/ATVBAHA.114.303791. Epub 2014 May 15.

13.

Spontaneously diabetic Ins2(+/Akita):apoE-deficient mice exhibit exaggerated hypercholesterolemia and atherosclerosis.

Jun JY, Ma Z, Segar L.

Am J Physiol Endocrinol Metab. 2011 Jul;301(1):E145-54. doi: 10.1152/ajpendo.00034.2011. Epub 2011 Mar 29.

14.

Overproduction of altered VLDL in an insulin-resistance rat model: Influence of SREBP-1c and PPAR-α.

Lucero D, Miksztowicz V, Macri V, López GH, Friedman S, Berg G, Zago V, Schreier L.

Clin Investig Arterioscler. 2015 Jul-Aug;27(4):167-74. doi: 10.1016/j.arteri.2014.11.002. Epub 2015 Mar 18.

PMID:
25796423
15.

[Dyslipidemia and atherosclerosis].

Koba S, Hirano T.

Nihon Rinsho. 2011 Jan;69(1):138-43. Review. Japanese.

PMID:
21226274
16.

Liver ABCA1 deletion in LDLrKO mice does not impair macrophage reverse cholesterol transport or exacerbate atherogenesis.

Bi X, Zhu X, Duong M, Boudyguina EY, Wilson MD, Gebre AK, Parks JS.

Arterioscler Thromb Vasc Biol. 2013 Oct;33(10):2288-96. doi: 10.1161/ATVBAHA.112.301110. Epub 2013 Jun 27.

17.

The androgen receptor confers protection against diet-induced atherosclerosis, obesity, and dyslipidemia in female mice.

Fagman JB, Wilhelmson AS, Motta BM, Pirazzi C, Alexanderson C, De Gendt K, Verhoeven G, Holmäng A, Anesten F, Jansson JO, Levin M, Borén J, Ohlsson C, Krettek A, Romeo S, Tivesten Å.

FASEB J. 2015 Apr;29(4):1540-50. doi: 10.1096/fj.14-259234. Epub 2014 Dec 30.

18.
19.

Apolipoprotein A-IV expression in mouse liver enhances triglyceride secretion and reduces hepatic lipid content by promoting very low density lipoprotein particle expansion.

VerHague MA, Cheng D, Weinberg RB, Shelness GS.

Arterioscler Thromb Vasc Biol. 2013 Nov;33(11):2501-8. doi: 10.1161/ATVBAHA.113.301948. Epub 2013 Sep 12.

PMID:
24030551
20.

Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes.

Vergès B.

Atherosclerosis. 2010 Aug;211(2):353-60. doi: 10.1016/j.atherosclerosis.2010.01.028. Epub 2010 Jan 29. Review.

PMID:
20189175

Supplemental Content

Support Center